nach oben

International Journal of Clinical Oncology

Erschienen in:

02.02.2016 | Original Article

Pre-ablation stimulated thyroglobulin is a better predictor of recurrence in pathological N1a papillary thyroid carcinoma than the lymph node ratio

verfasst von: Young Woo Chang, Hwan Soo Kim, Seung Pil Jung, Hoon Yub Kim, Jae Bok Lee, Jeoung Won Bae, Gil Soo Son

Erschienen in: International Journal of Clinical Oncology | Ausgabe 5/2016

Einloggen, um Zugang zu erhalten

Abstract

Background

Papillary thyroid carcinomas (PTC) with lymph node metastases have a high recurrence rate. We analyzed the potential of lymph node ratio (LNR) and the level of pre-ablation stimulated thyroglobulin (sTg) as risk factors predicting recurrence in patients with pathological N1a PTC.

Materials and methods

This study involved 192 patients with pathologically confirmed PTC and central neck lymph node metastases who underwent total thyroidectomy with central lymph node dissection (CLND). The clinico-pathological characteristics, the pre-ablation sTg level and post-treatment recurrences were examined. Univariate and multivariate analyses were performed to identify factors associated with recurrence in these patients.

Results

During a median follow-up of 63 months, 17 patients had loco-regional recurrences. Receiver operating characteristic curve analysis showed that the appropriate cut-off values for LNR and the pre-ablation sTg level was 0.48 and 9.3 ng/mL, respectively. Patients with LNR values of ≥0.48 had a significantly worse disease-free survival (DFS) than those with LNR values of <0.48 (P = 0.015), and patients with pre-ablation sTg level values of ≥9.3 ng/mL had significantly worse DFS than those with pre-ablation sTg level values <9.3 ng/mL (P < 0.001). Relative to patients with LNR values of <0.48, those with LNR values of ≥0.48 had higher median pre-ablation sTg level values (0.55 vs. 4.20; P < 0.001). The correlation covariant between the LNR value and the pre-ablation sTg level value was r = 0.454 (P < 0.001). Multivariate analysis showed that a LNR value of ≥0.48 (P = 0.386) was not an independent risk factor for recurrence. To the contrary, a pre-ablation sTg level value of ≥9.3 ng/mL (P < 0.001) was an independent risk factor for recurrence.

Conclusion

A high pre-ablation sTg level is a better predictor of recurrence in pathological N1a PTC than a high LNR value. Careful follow-up of patients with this risk factor is recommended.

Machens A, Hinze R, Thomusch O et al (2002) Pattern of nodal metastasis for primary and reoperative thyroid cancer. World J Surg 26:22–28CrossRefPubMed

Mazzaferri EL, Jhiang SM (1994) Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 97:418–428CrossRefPubMed

Lee YS, Kim SW, Kim SW et al (2007) Extent of routine central lymph node dissection with small papillary thyroid carcinoma. World J Surg 31:1954–1959CrossRefPubMed

Ricarte-Filho J, Ganly I, Rivera M et al (2012) Papillary thyroid carcinomas with cervical lymph node metastases can be stratified into clinically relevant prognostic categories using oncogenic BRAF, the number of nodal metastases, and extra-nodal extension. Thyroid 22:575–584CrossRefPubMed

Ryu IS, Song CI, Choi S-H et al (2014) Lymph node ratio of the central compartment is a significant predictor for locoregional recurrence after prophylactic central neck dissection in patients with thyroid papillary carcinoma. Ann Surg Oncol 21:277–283CrossRefPubMed

Lang BH-H, Wong KP, Wan KY et al (2012) Significance of metastatic lymph node ratio on stimulated thyroglobulin levels in papillary thyroid carcinoma after prophylactic unilateral central neck dissection. Ann Surg Oncol 19:1257–1263CrossRefPubMed

Jeon MJ, Yoon JH, Han JM et al (2013) The prognostic value of the metastatic lymph node ratio and maximal metastatic tumor size in pathological N1a papillary thyroid carcinoma. Eur J Endocrinol 168:219–225CrossRefPubMed

Van Herle AJ, Vassart G, Dumont JE (1979) Control of thyroglobulin synthesis and secretion. (First of two parts). N Engl J Med 301:239–249CrossRefPubMed

Ozata M, Suzuki S, Miyamoto T et al (1994) Serum thyroglobulin in the follow-up of patients with treated differentiated thyroid cancer. J Clin Endocrinol Metab 79:98–105PubMed

10.

Duren M, Siperstein AE, Shen W et al (1999) Value of stimulated serum thyroglobulin levels for detecting persistent or recurrent differentiated thyroid cancer in high- and low-risk patients. Surgery 126:13–19CrossRefPubMed

11.

Spencer CA, Takeuchi M, Kazarosyan M et al (1998) Serum thyroglobulin autoantibodies: prevalence, influence on serum thyroglobulin measurement, and prognostic significance in patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 83:1121–1127PubMed

12.

Bai LS, Chen C, Gong YP et al (2013) Lymph node ratio is more predictive than traditional lymph node stratification in lymph node positive invasive breast cancer. Asian Pac J Cancer Prev 14:753–757CrossRefPubMed

13.

Hong KD, Lee SI, Moon HY (2011) Lymph node ratio as determined by the 7th edition of the American Joint Committee on Cancer staging system predicts survival in stage III colon cancer. J Surg Oncol 103:406–410CrossRefPubMed

14.

Yip J, Orlov S, Orlov D et al (2013) Predictive value of metastatic cervical lymph node ratio in papillary thyroid carcinoma recurrence. Head Neck 35:592–598CrossRefPubMed

15.

Mekenkamp LJM, van Krieken JHJM, Marijnen CAM et al (2009) Lymph node retrieval in rectal cancer is dependent on many factors—the role of the tumor, the patient, the surgeon, the radiotherapist, and the pathologist. Am J Surg Pathol 33:1547–1553CrossRefPubMed

16.

Ahn BH, Kim JR, Jeong HC et al (2015) Predictive factors of central lymph node metastasis in papillary thyroid carcinoma. Ann Surg Treat Res 88:63–68CrossRefPubMedPubMedCentral

17.

Chang YW, Kim HS, Kim HY et al (2015) Should central lymph node dissection be considered for all papillary thyroid microcarcinoma? Asian J Surg. doi:10.1016/j.asjsur.2015.02.006 (in press)

18.

Max MH, Scherm M, Bland KI (1983) Early and late complications after thyroid operations. South Med J 76:977–980CrossRefPubMed

19.

Henry JF, Gramatica L, Denizot A et al (1998) Morbidity of prophylactic lymph node dissection in the central neck area in patients with papillary thyroid carcinoma. Langenbecks Arch Surg 383:167–169CrossRefPubMed

20.

Pacini F, Lari R, Mazzeo S et al (1985) Diagnostic value of a single serum thyroglobulin determination on and off thyroid suppressive therapy in the follow-up of patients with differentiated thyroid cancer. Clin Endocrinol (Oxf) 23:405–411CrossRef

21.

Clark OH, Gerend PL (1985) Thyrotropin receptor–adenylate cyclase system in Hurthle cell neoplasms. J Clin Endocrinol Metab 61:773–778CrossRefPubMed

22.

Girelli ME, Busnardo B, Amerio R et al (1986) Critical evaluation of serum thyroglobulin (Tg) levels during thyroid hormone suppression therapy versus Tg levels after hormone withdrawal and total body scan: results in 291 patients with thyroid cancer. Eur J Nucl Med 11:333–335CrossRefPubMed

Titel: Pre-ablation stimulated thyroglobulin is a better predictor of recurrence in pathological N1a papillary thyroid carcinoma than the lymph node ratio
verfasst von: Young Woo Chang
Hwan Soo Kim
Seung Pil Jung
Hoon Yub Kim
Jae Bok Lee
Jeoung Won Bae
Gil Soo Son
Publikationsdatum: 02.02.2016
Verlag: Springer Japan
Erschienen in: International Journal of Clinical Oncology / Ausgabe 5/2016
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-016-0956-2

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Pre-ablation stimulated thyroglobulin is a better predictor of recurrence in pathological N1a papillary thyroid carcinoma than the lymph node ratio